Merck has informed that the 51st Annual General Meeting of the company was held on Friday, June 01, 2018. The meeting commenced at 3.00 p.m. (IST) and concluded at 7.00 PM (IST).The following resolutions as set out in the Notice were put up for the Members approval by way of e-voting/postal ballot: Consideration and adoption of Financial Statements for the year 2017; declaration of Dividend for financial year 2017; re-appointment of Director in place of N. Krishnan who retires by rotation and, being eligible, offers himself for re-appointment; appointment of Milind Thatte as Director and the Managing Director (DIN: 08092990) for a period of Five Years and to fix his remuneration; ratification of Appointment of Haribhakti & Co. LLP as Statutory Auditors of the Company; payment of Commission to Non-Executive Independent Director; fixing the remuneration of Cost Auditor; and approving the Related Party transactions/arrangements with Merck KGaA, Germany.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: